Guidelines for the diagnosis and management of gastroesophageal reflux disease: An evidence-based consensus

Arquivos de Gastroenterologia

Volumn 47, Issue 1, 2010, Pages 99-115

  Moraes Filho, Joaquim Prado P ^a   Navarro Rodriguez, Tomas ^a,b   Barbuti, Ricardo ^a,b   Eisig, Jaime ^a,b   Chinzon, Decio ^a,b   Bernardo, Wanderley ^b   Carvalhaes, Aloisio ^b   Ferrari, Angelo P ^b   Magalhaes, Antonio Frederico N ^b   Nasi, Ary ^b   Paula E Silva, Celso M ^b   Hashimoto, Claudio ^b   Silva, Edson P ^b   Moura, Eduardo ^b   Lemme, Eponina ^b   Nader, Farid ^b   Maluf Filho, Fauze ^b   Domingues, Gerson ^b   Barreto, Igelmar ^b   Jorge Filho, Isac ^b   Maguilnik, Ismael ^b   Cecconello, Ivan ^b   Moraes Filho, Joaquim P ^b   Rezende Filho, Joffre ^b   Modena, José Luis P ^b   De Almeida, Jose Roberto ^b   Aprile, Lilian ^b   Camacho Lobato, Luciana ^b   Moretzohn, Luciana ^b   Cury, Marcelo ^b   Tolentino, Marcio ^b   Santo, Marco Aurelio ^b   Kleiner, Marcos ^b   Haddad, Marcus T ^b   Passos, Maria Do Carmo ^b   Mion, Olavo G ^b   Malafaia, Oswaldo ^b   Rocha, Paulo S ^b   Stelmach, Rafael ^b   Correa, Ricardo A ^b   Gursky, Richard ^b   Azzam, Rimon S ^b   El Ibrahim, Roberto ^b   Dantas, Roberto ^b   Sallum, Rubens ^b   Zaterka, Schlioma ^b   Barros, Sergio ^b   Meneghelli, Ulysses ^b   Pollara, Wilson ^b   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brazilian Medical Association   (Brazil)

Author keywords

Esophagitis, peptic; Gastroesophageal reflux; Guidelines as topic

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RANITIDINE;

CONFERENCE PAPER; ESOPHAGITIS; ESOPHAGUS PH; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HELICOBACTER INFECTION; HIATUS HERNIA; HISTOPATHOLOGY; HUMAN; INTERCELLULAR SPACE; LOW DRUG DOSE; LOWER ESOPHAGUS SPHINCTER; MEDICAL PRACTICE; PRACTICE GUIDELINE; QUESTIONNAIRE; RECURRENCE RISK; SLEEP DISORDER; STOMACH FUNDOPLICATION;

EVIDENCE-BASED MEDICINE; GASTROESOPHAGEAL REFLUX; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 77953179017     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032010000100017     Document Type: Conference Paper

References (150)

1. Achem SR, Kolts BE, MacMath T, Richter J, Mohr D, Burton L, Castell DO. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 1997;42:2138-2145 (Pubitemid 27502004)
2. Ahlawat SK, Moh-Ud-Din R, Williams DC, Maher KA, Benjamin SB. A prospective study of gastric acid analysis and esophageal acid exposure in patients with gastroesophageal reflux refractory to medical therapy. Dig Dis Sci. 2005;50:2019-2024
3. Anvari M, Allen C. Surgical outcome in gastro-esophageal reflux disease patients with inadequate response to proton pump inhibitors. Surg Endosc. 2003;17:1029-1035 (Pubitemid 36808092)
4. Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, Goldsmith C. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov. 2006;13:238-249 (Pubitemid 44942370)
5. Bajbouj M, Becker V, Neuber M, Schmid RM, Meining A. Combined pH-metry/impedance monitoring increases the diagnostic yield in patients with atypical gastroesophageal reflux symptoms. Digestion. 2007;76:223-228 (Pubitemid 351351678)
6. Baldi F, Cappiello R, Cavoli C, Ghersi S, Torresan F, Roda E. Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. World J Gastroenterol. 2006;12:82-88 (Pubitemid 43126088)
7. Bensenor IM, Hatanaka VMA. Diagnóstico clínico. In: Dantos IS, Silva LBB, Lotufo PA, Bensenor IM, editores. Clínica médica - diagnóstico e tratamento. São Paulo: Sarvier; 2008. p.10-24.
8. Berg S, Hoffstein V, Gislason T. Acidification of distal esophagus and sleep-related breathing disturbances. Chest. 2004;125:2101-2106 (Pubitemid 38788176)
9. Booth MI, Stratford J, Jones L, Dehn TC. Randomized clinical trial of laparoscopic total (Nissen) versus posterior partial (Toupet) fundoplication for gastro-oesophageal reflux disease based on preoperative oesophageal manometry. Br J Surg. 2008;95:57-63. (Pubitemid 351184915)
10. Calabrese C, Bortolotti M, Fabbri A, Areni A, Cenacchi G, Scialpi C, Miglioli M, Di Febo G. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol. 2005;100:537-542 (Pubitemid 40487549)
11. Calabrese C, Trerè D, Fabbri A, Cenacchi G, Vici M, Derenzini M, Di Febo G. Endoscopic appearance of GERD: putative role of cell proliferation. Dig Liver Dis. 2007;39:713-719 (Pubitemid 47046639)
12. Caletti GC, Ferrari A, Mattioli S, Zannoli R, Di Simone MP, Bocus P, Gozzetti G, Barbara L. Endoscopy versus endoscopic ultrasonography in staging reflux esophagitis. Endoscopy. 1994;26:794-797
13. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol. 1999;94:2054-2059
14. Carling L, Axelsson CK, Forssell H, Stubberöd A, Kraglund K, Bonnevie O, Ekström P. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther. 1998;12:985-990 (Pubitemid 28454381)
15. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-583 (Pubitemid 34245883)
16. Cats A, Schenk BE, Bloemena E, Roosedaal R, Lindeman J, Biemond I, Klinkenberg-Knol EC, Meuwissen SG, Kuipers EJ. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684-690 (Pubitemid 30445471)
17. Caviglia R, Ribolsi M, Gentile M, Rabitti C, Emerenziani S, Guarino MP, Petitti T, Cicala M. Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:629-636 (Pubitemid 46255856)
18. Chiocca JC, Olmos JA, Salis GB, Soifer LO, Higa R, Marcolongo M. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther. 2005;22:331-342 (Pubitemid 41207463)
19. Cookson R, Flood C, Koo B, Mahon D, Rhodes M. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease. Br J Surg. 2005;92:700-706 (Pubitemid 40863188)
20. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1999;13:49-57.
21. Delchier JC, Cohen G, Humphries TJ. Rabeprazole 20 mg once daily or 10 mg twice daily is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastroesophageal reflux disease. Scand J Gastroenterol. 2000;35:1245-1250 (Pubitemid 32051636)
22. des Varannes SB, Sacher-Huvelin S, Vavasseur F, Masliah C, Le Rhun M, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. World J Gastroenterol. 2006;12:2569-2573
23. Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006;4:852-859
24. Dickman R, Green C, Fass SS, Quan SF, Dekel R, Risner-Adler S, Fass R. Relationships between sleep quality and pH monitoring fndings in persons with gastroesophageal reflux disease. J Clin Sleep Med. 2007;3:505-513 (Pubitemid 47378254)
25. dos Santos LH, Ribeiro IO, Sánchez PG, Hetzel JL, Felicetti JC, Cardoso PF. Evaluation of pantoprazol treatment response of patients with asthma and gastroesophageal reflux: a randomized prospective double-blind placebo-controlled study. J Bras Pneumol. 2007;33:119-127
26. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001;96:979-983 (Pubitemid 32319125)
27. El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastrooesophageal reflux disease: a cross sectional study in volunteers. Gut. 2005;54:11-17 (Pubitemid 40007212)
28. Endzinas Z, Jonciauskiene J, Mickevicius A, Kiudelis M. Hiatal hernia recurrence after laparoscopic fundoplication. Medicina (Kaunas). 2007;43:27-31.
29. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999;44(suppl 2):s1-s16.
30. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632 (Pubitemid 34173813)
31. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2005;21:455-463 (Pubitemid 40313949)
32. Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol. 2005;11:3091-3098
33. Franchi A, Brogelli B, Massi D, Santucci M, De Campora E, Gallo O. Dilation of intercellular spaces is associated with laryngo-pharyngeal reflux: an ultrastructural morphometric analysis of laryngeal epithelium. Eur Arch Otorhinolaryngol. 2007;264:907-911 (Pubitemid 47025065)
34. Fraser AG, Morton RP, Gillibrand J. Presumed laryngo-pharyngeal reflux: investigate or treat? J Laryngol Otol. 2000;114:441-447
35. French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease 'Diagnosis and Treatment': report of a meeting held in Paris, France, on 21-22 January 1999. The Jury of the consensus conference. Eur J Gastroenterol. 2000;12:129-137
36. Fujiwara Y, Machida A, Watanabe Y, Shiba M, Tominaga K, Watanabe T, Oshitani N, Higuchi K, Arakawa T. Association between dinner-to-bed time and gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:2633-2636 (Pubitemid 43919628)
37. Fuller CB, Hagen JA, DeMeester TR, Peters JH, Ritter M, Bremmer CG. The role of fundoplication in the treatment of type II paraesophageal hernia. Thorac Cardiovasc Surg. 1996;111:655-661 (Pubitemid 26087731)
38. Gatopoulou A, Mimidis K, Giatromanolaki A, Papadopoulos V, Polychronidis A, Lyratzopoulos N, Sivridis E, Minopoulos G. Impact of hiatal hernia on histological pattern of non-erosive reflux disease. BMC Gastroenterol. 2005;9:2. (Pubitemid 41363856)
39. Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol. 2008;103:267-275 (Pubitemid 351248746)
40. Gillessen A, Beil W, Modlin IM, Gatz G, Hole U. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol. 2004;38:332-340 (Pubitemid 38393069)
41. Gillies RS, Stratford JM, Booth MI, Dehn TC. Oesophageal pH monitoring using the Bravo catheter-free radio capsule. Eur J Gastroenterol Hepatol. 2007;19:57-63.
42. Gillies RS, Stratford JM, Booth MI, Dehn TC. Does laparoscopic antireflux surgery improve quality of life in patients whose gastro-oesophageal reflux disease is well controlled with medical therapy? Eur J Gastroenterol Hepatol. 2008;20:430-435
43. Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007;75(suppl 1):69-78.
44. Goh KL, Benamouzig R, Sander P, Schwan T; EMANCIPATE. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol. 2007;19:205-211 (Pubitemid 46263276)
45. Guda N, Partington S, Shaw MJ, Leo G, Vakil N. Unrecognized GERD symptoms are associated with excessive daytime sleepiness in patients undergoing sleep studies. Dig Dis Sci. 2007;52:2873-2876 (Pubitemid 47373919)
46. Hagedorn C, Lönroth H, Rydberg L, Ruth M, Lundell L. Long-term efficacy of total (Nissen-Rossetti) and posterior partial (Toupet) fundoplication: results of a randomized clinical trial. J Gastrointest Surg. 2002;6:540-545 (Pubitemid 40433506)
47. Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988;33:518-522
48. Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med. 1996;100:395-405.
49. Hila A, Agrawal A, Castell DO. Combined multichannel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol. 2007;5:172-177 (Pubitemid 46216940)
50. Ing AJ, Ngu MC, Breslin AB. Obstructive sleep apnea and gastroesophageal reflux. Am J Med. 2000;108(suppl 4A):120s-5s.
51. Johnson DA, Orr WC, Crawley JA, Traxler B, McCullough J, Brown KA, Roth T. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100:1914-1922 (Pubitemid 43919381)
52. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol. 2002;37:642-647 (Pubitemid 34620924)
53. Johnsson F, Hatlebakk JG, Klintenberg AC, Román J. Symptom relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol. 2003;38:347-353 (Pubitemid 36606303)
54. Johnsson F, Hatlebakk JG, Klintenberg AC, Román J, Toth E, Stubberöd A, Falk A, Edin R. One-week omeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Scand J Gastroenterol. 2003;38:354-359 (Pubitemid 36606304)
55. Jones MP, Sloan SS, Rabine JC, Ebert CC, Huang CF, Kahrilas PJ. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:1711-1717
56. Jones RB, Lydeard SE, Hobbs FD, Kenkre JE, Williams EL, Jones SJ, Repper JA, Caldow JL, Dunwoodie WM, Bottomley JM. Dyspepsia in England and Scotland. Gut. 1990;31:401-405
57. Kadakia SC, Kikendall JW, Maydonovitch C, Johnson LF. Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring. Am J Gastroenterol. 1995;90:1785-1790
58. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther. 2000;14:1249-1258
59. Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50:2009-2018 (Pubitemid 41504082)
60. Kamolz T, Granderath FA, Schweiger UM, Pointner R. Laparoscopic Nissen fundoplication in patients with nonerosive reflux disease. Long-term quality-of-life assessment and surgical outcome. Surg Endosc. 2005;19:494-500.
61. Kawamura O, Sekiguchi T, Kusano M, Horikoshi T, Kikuchi K, Miyazaki M, Yamada T, Ohwada T. Endoscopic ultrasonographic abnormalities and lower esophageal sphincter function in reflux esophagitis. Dig Dis Sci. 1995;40:598-605.
62. Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther. 1999;13:675-678 (Pubitemid 29219034)
63. Kim JH, Rhee PL, Park EH, Son HJ, Kim JJ, Rhee JC. Clinical usefulness of subgrouping of patients with non-cardiac chest pain according to characteristic symptoms in Korea. J Gastroenterol Hepatol. 2007;22:320-325
64. Kim N, Lee SW, Cho SI, Park CG, Yang CH, Kim HS, Rew JS, Moon JS, Kim S, Park SH, Jung HC, Chung IS; H. pylori and Gerd Study Group of Korean College of Helicobacter and Upper Gastrointestinal Research. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther. 2008;27:173-185
65. Kjellin A, Ramel S, Rossner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol. 1996;31:1047-1051 (Pubitemid 26373931)
66. Klaus A, Gadenstaetter M, Mühlmann G, Kirchmayr W, Profanter C, Achem SR, Wetscher GJ. Selection of patients with gastroesophageal reflux disease for antireflux surgery based on esophageal manometry. Dig Dis Sci. 2003;48:1719-1722 (Pubitemid 37174722)
67. Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M, Gatz G. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion. 2003;67:6-13.
68. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HP, Dent J, Zeitoun P, Havu N, Lamm M, Walan A. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004;53:12-20. (Pubitemid 38083004)
69. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Eklund S; Expo Study Investigators. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21:739-746 (Pubitemid 40476079)
70. Lauritsen K, Devière J, Bigard MA, Bayerdörffer E, Mózsik G, Murray F, Kristjánsdóttir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L, Fried M, Morris J, Schneider H, Eklund S, Larkö A; Metropole study results. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther. 2003;17:333-341
71. Lightdale CJ, Schmitt C, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51:852-857 (Pubitemid 44030802)
72. Littner MR, Leung F W, Ballard ED 2nd, Huang B, Samra NK; Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128:1128-1135
73. Livingston CD, Jones HL Jr, Askew RE Jr, Victor BE, Askew RE Sr. Laparoscopic hiatal hernia repair in patients with poor esophageal motility or paraesophageal herniation. Am Surg. 2001;67:987-991
74. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456
75. Lundell L, Ruth M, Sandberg N, Bove-Nielsen M. Does massive obesity promote abnormal gastroesophageal reflux? Dig Dis Sci. 1995;40:1632-1635
76. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Lamm M, Blomqvist A, Hatlebakk JG, Janatuinen E, Levander K, Nyström P, Wiklund I. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol. 2000;12:879-887 (Pubitemid 30663900)
77. Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, Levander K, Hatlebakk JG, Liedman B, Lamm M, Malm A, Walan A; Nordic Gerd Study Group. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006;23:639-647
78. Lundell L, Attwood S, Ell C, Fiocca R, Galmiche JP, Hatlebakk J, Lind T, Junghard O; LOTUS trial collaborators. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 2008;57:1207-1213
79. Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus. 2004;17:274-278 (Pubitemid 40123800)
80. Mahon D, Rhodes M, Decadt B, Hindmarsh A, Lowndes R, Beckingham I, Koo B, Newcombe RG. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. Br J Surg. 2005;92:695-699 (Pubitemid 40863187)
81. Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastrooesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg. 2006;93:1483-1487 (Pubitemid 44893649)
82. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398-1402 (Pubitemid 44476780)
83. Mark LA, Okrainec A, Ferri LE, Feldman LS, Mayrand S, Fried GM. Comparison of patient-centered outcomes after laparoscopic Nissen fundoplication for gastroesophageal reflux disease or paraesophageal hernia. Surg Endosc. 2008;22:343-347
84. Mathus-Vliegen EM, Tygat GN. Gastrooesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37:1246-1252
85. Mattioli S, D'Ovidio F, Di Simone MP, Bassi F, Brusori S, Pilotti V, Felice V, Ferruzzi L, Guernelli N. Clinical and surgical relevance of the progressive phases of intrathoracic migration of the gastroesophageal junction in gastroesophageal reflux disease. J Thorac Cardiovasc Surg. 1998;116:267-275 (Pubitemid 28367093)
86. Maziak DE, Todd TR, Pearson FG. Massive hiatus hernia: evaluation and surgical management. J Thorac Cardiovasc Surg. 1998;115:53-60.
87. Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up. J Gastrointest Surg. 2006;10:1312-1316 (Pubitemid 44750742)
88. Meineche-Schmidt V, Juhl HH, Østergaard JE, Luckow A, Hvenegaard A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther. 2004;19:907-915
89. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, Dixon MF. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5:206-214 (Pubitemid 34948002)
90. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology. 2001;121:1120-1126 (Pubitemid 33022092)
91. Mönnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2007;75(suppl 1):62-68
92. Moraes-Filho JPP, Cecconello I, Gama-Rodrigues J, Castro LP, Henry MA, Meneghelli UG, Quigley E. Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management. Am J Gastroenterol. 2002;97:241-248 (Pubitemid 34160745)
93. Moraes-Filho JPP, Chinzon D, Eisig JN, Hashimoto CL, Zaterka S. Prevalence of heartburn and gastroesophageal reflux disease in the urban Brazilian population. Arq Gastroenterol. 2005;42:122-127 (Pubitemid 41134023)
94. Morgenthal CB, Lin E, Shane MD, Hunter JG, Smith CD. Who will fail laparoscopic Nissen fundoplication? Preoperative prediction of long-term outcomes. Surg Endosc. 2007;21:1978-1984 (Pubitemid 47620292)
95. Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, van Milligen de Wit AW, de Groot GH; Dutch Omeprazole MUPS Study Group. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. Eur J Gastroenterol Hepatol. 2002;14:649-656
96. Myrvold HE, Lundell L, Miettinen P, Pedersen SA, Liedman B, Hatlebakk J, Julkunen R, Levander K, Lamm M, Mattson C, Carlsson J, Ståhlhammar NO; Nordic GORD Study Group. The cost of long term therapy for gastro-oesophageal reflux disease: a randomized trial comparing omeprazole and open antireflux surgery. Gut. 2001;49:488-494
97. Nandurkar S, Locke GR 3rd, Fett S, Zinsmeister AR, Cameron AJ, Talley NJ. Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther. 2004;20:497-505.
98. Nocon M, Labenz J, Willich SN. Lifestyle factors and symptoms of gastrooesophageal reflux - a population-based study. Aliment Pharmacol Ther. 2006;23:169-174
99. Noordzij JP, Khidr A, Desper E, Meek RB, Reibel JF, Levine PA. Correlation of pH probe-measured laryngopharyngeal reflux with symptoms and signs of reflux laryngitis. Laryngoscope. 2002;112:2192-2195
100. Patterson RN, Johnston BT, MacMahon J, Heaney LG, McGarvey LP. Oesophageal pH monitoring is of limited value in the diagnosis of, "reflux-cough. Eur Respir J. 2004;24:724-7.
101. Pehl C, Wendl B, Pfeiffer A. White wine and beer induce gastro-oesophageal reflux in patients with reflux disease. Aliment Pharmacol Ther. 2006;23:1581-1586
102. Penagini R, Mangano M, Bianchi PA. Effect of increasing the fat content but not the energy load of a meal on gastro-oesophageal reflux and lower oesophageal sphincter motor function. Gut. 1998;42:330-333
103. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes RB, Dawes M. Oxford Centre for evidence-based Medicine. Levels of evidence; May 2001.
104. Piesman M, Hwang I, Maydonovitch C, Wong RK. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol. 2007;102:2128-2134
105. Piloto RR, Fama F, Giacobbe G, Gioffre Florio MA, Cogliandolo A. Quality of life and predictors of long-term outcome in patients undergoing open Nissen fundoplication for chronic gastroesophageal reflux. Am J Surg. 2006;191:470-478
106. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18:370-373 (Pubitemid 43904763)
107. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE 2nd, Pellegrini CA. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136-142 (Pubitemid 43092677)
108. Richter JE, Kovacs TO, Greski-Rose PA, Huang section sign B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999;13:795-804.
109. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol. 2000;95:3071-3080
110. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001;96:3089-3098 (Pubitemid 33095346)
111. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B; European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol. 2005;17:559-566
112. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB Jr, Gardner JD. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. Dig Dis Sci. 2002;47:265-273 (Pubitemid 34123983)
113. Roman S, Poncet G, Serraj I, Zerbib F, Boulez J, Mion F. Characterization of reflux events after fundoplication using combined impedance-pH recording. Br J Surg. 2007;94:48-52. (Pubitemid 46142731)
114. Rosaida MS, Goh KL. Gastro-oesophageal reflux disease, reflux oesophagitis and nonerosive reflux disease in a multiracial Asian population: a prospective, endoscopy based study. Eur J Gastroenterol Hepatol. 2004;16:495-501.
115. Rossi M, Barreca M, de Bortoli N, Renzi C, Santi S, Gennai A, Bellini M, Costa F, Conio M, Marchi S. Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann Surg. 2006;243:58-63. (Pubitemid 43054055)
116. Santos LH, Ribeiro IO, Sánchez PG, Hetzel JL, Felicetti JC, Cardoso P F. Evaluation of pantoprazol treatment response of patients with asthma and gastroesophageal reflux: a randomized prospective double-blind placebo-controlled study. J Bras Pneumol. 2007;33:119-127
117. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, Schrijver M, Dieleman LA, Meuwissen SG. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997;92:1997-2000. (Pubitemid 27476237)
118. Schindlbeck NE, Heinrich C, Dendorfer A, Pace F, Muller-Lissner SA. Influence of smoking and esophageal intubation on esophageal pH-metry. Gastroenterology. 1987;92:1994-1997 (Pubitemid 17072251)
119. Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51:844-850 (Pubitemid 44030800)
120. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther. 2003;18:587-594 (Pubitemid 37186608)
121. Sermon F, Vanden Brande S, Roosens B, Mana F, Deron P, Urbain D. Is ambulatory 24-h dual-probe pH monitoring useful in suspected ENT manifestations of GERD? Dig Liver Dis. 2004;36:105-110
122. Sgouros SN, Mpakos D, Rodias M, Vassiliades K, Karakoidas C, Andrikopoulos E, Stefanidis G, Mantides A. et al. Prevalence and axial length of
123. Sharma B, Sharma M, Daga MK, Sachdev GK, Bondi E. Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. World J Gastroenterol. 2007;13:1706-1710 (Pubitemid 46711342)
124. Sharma N, Agrawal A, Freeman J, Vela MF, Castell D. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol. 2008;6:521-524
125. Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut. 2005;54:449-454 (Pubitemid 40395491)
126. Solcia E, Villani L, Luinetti O, Trespi E, Strada E, Tinelli C, Fiocca R. Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch. 2000;436:207-216 (Pubitemid 30168678)
127. Stanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion. 1977;15:104-109
128. Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl. 1999;231:29-37. (Pubitemid 29510675)
129. Stolte M, Vieth M, Schmitz JM, Alexandridis T, Seifert E. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological fndings in the lower oesophagus. Scand J Gastroenterol. 2000;35:1125-1130
130. Strate U, Emmermann A, Fibbe C, Layer P, Zornig C. Laparoscopic fundoplication: Nissen versus Toupet two-year outcome of a prospective randomized study of 200 patients regarding preoperative esophageal motility. Surg Endosc. 2008;22:21-30.
131. Sweet MP, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C, Theodore PR. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg. 2007;133:1078-1084 (Pubitemid 46435907)
132. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci. 2000;45:845-853
133. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1804-1808 (Pubitemid 29008818)
134. Torres-Quevedo R, Manterola C, Sanhueza A, Bustos L, Pineda V, Vial M. Diagnostic properties of a symptoms scale for diagnosing reflux esophagitis. J Clin Epidemiol. 2008; 62:97-101.
135. Tsai HH, Chapman R, Shepherd A, McKeith D, Anderson M, Vearer D, Duggan S, Rosen JP; COMMAND Study Group. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther. 2004;20:657-665 (Pubitemid 39279054)
136. Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol. 2008;103:1090-1096 (Pubitemid 351677992)
137. Vaezi MF, Richter JE, Stasney CR, Spiegel JR, Iannuzzi RA, Crawley JA, Hwang C, Sostek MB, Shaker R. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116:254-260 (Pubitemid 44383934)
138. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920
139. Vieth M, Kulig M, Leodolter A, Nauclér E, Jaspersen D, Labenz J, Meyer-Sabellek W, Lind T, Willich S, Malfertheiner P, Stolte M. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther. 2006;23:313-319
140. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A, et al. A comparison of fve maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106-1110
141. Wang JH, Luo J Y, Dong L, Gong J, Tong M. Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi'an of Northwest China. World J Gastroenterol. 2004;10:1647-1651 (Pubitemid 38786948)
142. Waring JP, Eastwood TF, Austin JM, Sanowski RA. The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. Am J Gastroenterol. 1989;84:1076-1078
143. Weigt J, Mönkemüller K, Peitz U, Malfertheiner P. Multichannel intraluminal impedance and pH-metry for investigation of symptomatic gastroesophageal reflux disease. Dig Dis 2007;25:179-182 (Pubitemid 350194164)
144. Wenner J, Johnsson F, Johansson J, Oberg S. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102:239-245 (Pubitemid 46160535)
145. Wetscher GJ, Glaser K, Gadenstaetter M, Profanter C, Hinder RA. The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. Am J Surg. 1999;177: 189-192 (Pubitemid 29183870)
146. Wijnhoven BP, Lally CJ, Kelly JJ, Myers JC, Watson DI. Use of antireflux medication after antireflux surgery. J Gastrointest Surg. 2008;12:510-517
147. Wo JM, Koopman J, Harrell SP, Parker K, Winstead W, Lentsch E. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol. 2006;101:1972-1978 (Pubitemid 44337618)
148. Wu JC, Chan FK, Ching J Y, Leung WK, Hui Y, Leong R, Chung SC, Sung JJ. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut. 2004;53: 174-179 (Pubitemid 38125502)
149. Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, Savarino E, Parodi A, Mansi C, Fiocca R. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005;100:2299-2306 (Pubitemid 43919734)
150. Zornig C, Strate U, Fibbe C, Emmermann A, Layer P. Nissen vs Toupet laparoscopic fundoplication. Surg Endosc. 2002;16:758-766